METHODS FOR THE DIAGNOSIS AND TREATMENT OF NEUROLOGICAL DISORDERS

• US 20190333629A1
• Filed: 12/06/2018
• Published: 10/31/2019
• Est. Priority Date: 11/11/2011
• Status: Active Grant

• Current Assignee: Rutgers University
• Original Assignee: Rutgers University
• Inventors: Torres, Elizabeth B.
• Granted Patent: US 11,270,790 B2
• Time in Patent Office: Days
• CPC Class Codes: A61B 5/0015 characterised by features of the telemetry system
• CPC Class Codes: A61B 5/11 Measuring movement of the entire body or parts thereof, e.g. head or hand tremor, mobility of a limb for measuring pulse A61B5/02 ;A61B5/1038 takes precedence; motion detection to correct for motion artifacts in physiological signals A61B5/721
• CPC Class Codes: A61B 5/1104 induced by stimuli or drugs; A61B5/1102 takes precedence; investigating medicinal preparations G01N33/15
• CPC Class Codes: A61B 5/1114 Tracking parts of the body
• CPC Class Codes: A61B 5/1124 Determining motor skills
• CPC Class Codes: A61B 5/1125 Grasping motions of hands
• CPC Class Codes: A61B 5/1128 using image analysis A61B5/1127 takes precedence
• CPC Class Codes: A61B 5/162 Testing reaction times
• CPC Class Codes: A61B 5/168 Evaluating attention deficit, hyperactivity
• CPC Class Codes: A61B 5/40 Detecting, measuring or recording for evaluating the nervous system A61B5/4806, A61B5/4821, A61B5/4824 take precedence
• CPC Class Codes: A61B 5/4076 Diagnosing or monitoring particular conditions of the nervous system A61B5/4821, A61B5/4824 take precedence
• CPC Class Codes: A61B 5/4082 Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette
• CPC Class Codes: A61B 5/4088 Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia
• CPC Class Codes: A61B 5/4094 Diagnosing or monitoring seizure diseases, e.g. epilepsy
• CPC Class Codes: A61B 5/4848 Monitoring or testing the effects of treatment, e.g. of medication
• CPC Class Codes: A61B 5/7264 Classification of physiological signals or data, e.g. using neural networks, statistical classifiers, expert systems or fuzzy systems neural networks per se G06N3/00; expert systems per se G06N5/00
• CPC Class Codes: A61B 5/7275 Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
• CPC Class Codes: A61B 5/7278 Artificial waveform generation or derivation, e.g. synthesising signals from measured signals A61B5/327 takes precedence
• CPC Class Codes: G16H 10/60 for patient-specific data, e.g. for electronic patient records
• CPC Class Codes: G16H 20/70 relating to mental therapies, e.g. psychological therapy or autogenous training
• CPC Class Codes: G16H 40/20 : for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
• CPC Class Codes: G16H 50/20 : for computer-aided diagnosis, e.g. based on medical expert systems
• CPC Class Codes: G16Z 99/00 : Subject matter not provided for in other main groups of this subclass
• CPC Class Codes: H04L 63/0428 : wherein the data content is protected, e.g. by encrypting or encapsulating the payload

Abstract

The present invention provides objective methods of diagnosis and behavioural treatments of neurological disorders such as autism spectral disorders and Parkinson'"'"'s disease.

Claims

1-17. -17. (canceled)

18. A method for diagnosing a neurological disorder in a subject, said method comprising:

a. presenting on a display device an artificial agent to a subject, wherein the artificial agent produces a stimulus change to the subject when the subject interacts with the artificial agent;

b. measuring motion resulting from activation of a muscle of the subject, whereby motion measurements are produced;

c. separating the motion measurements into a first phase associated with leading up to and causing an interaction with the artificial agent, which interaction causes the artificial agent to produce the stimulus change, and a second phase associated with withdrawal from interaction with the artificial agent, which withdrawal causes the artificial agent not to produce the stimulus change;

d. determining automatically on a processor a first value of a distance between a first value of a statistic of the motion measurements that belong to the first phase and a second value of the statistic of the motion measurements that belong to the second phase;

e. determining automatically on a processor a measure of a neurological disorder in the subject based on a difference between the first value of the distance and a second value of the distance for a different second subject without the neurological disorder; and

f. presenting the measure of the neurological disorder on a display device.

19. The method of claim 18, wherein said neurological disorder is an autism spectral disorder (ASD) or Parkinson'"'"'s disease (PD).

20. The method of claim 18, wherein said artificial agent is a robot, three dimensional animate, speaker, or screen.

21. The method of claim 18, wherein said artificial agent is a dynamic media or interface.

22. The method of claim 18, wherein said artificial agent provides a task to the subject.

23. The method of claim 22, wherein said task is a pointing task or a match-to-sample task.

24. The method of claim 18, wherein said subject is not provided instruction on how to interact with the artificial agent.

25. The method of claim 18, wherein said artificial agent provides a stimulus when the subject contacts a region of interest.

26. The method of claim 25, wherein said artificial agent is a screen and the stimulus is a real-time video of the subject.

27. The method of claim 18, wherein said measuring motion resulting from activation of a muscle of the subject comprises measuring facial patterns of the subject.

28. The method of claim 18, further comprising:

f) after said steps a through e, administering a therapy to the subject;

g) after said administering the therapy, repeating said steps a through e to determine a post therapy measure of the neurological disorder;

h) determining a change between the measure of the neurological disorder and the post therapy measure of the neurological disorder; and

i) determining whether the therapy modulates the neurological disorder based on the change.

29. The method of claim 18, further comprising, after said steps a through e:

changing the stimulus produced by the artificial agent to lessen the difference between the first value of the distance and the second value of the distance; and

, repeating steps a through e.